Morningstar

Morningstar, Inc.

Equity Bottom-Up

Jazz Pharmaceuticals found large success with narcolepsy treatment Xyrem and is now transforming into a diversified orphan-focused pharmaceutical firm for life after Xyrem. While the firm still has a way to go, its Exemplary stewardship and successful execution of Xyrem's tricky pricing situation give us confidence in its ability to execute. However, given the uncertainty around the entry of Xyrem generics and Jazz’s lack of diversification in its current portfolio, we believe there is a risk…

We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year
Lead therapy Xyrem for narcolepsy…

Ireland

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00